Hint mode is switched on Switch off
For swift navigation between sections

Sangamo Therapeutics
LEI 2549006WMRKRC4G32Z67

PDF download

Choose all Reset all
Download Cancel
Organization name
Sangamo Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy.

Awards

News

14/07/2026 Sangamo Therapeutics: Bankruptcy Or Receivership, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing
24/06/2026 Sangamo Therapeutics: Change In Registrant’s Certifying Accountant, Other Events, Financial Statements And Exhibits
18/06/2026 Sangamo Therapeutics: Entry Into A Material Definitive Agreement, Bankruptcy Or Receivership, Creation Of A Direct Financial Obligation Or An Obligation Under An, Costs Associated With Exit Or Disposal Activities
18/06/2026 Sangamo Therapeutics: Financial Statements And Exhibits
03/02/2026 Sangamo Therapeutics: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    2549006WMRKRC4G32Z67
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001001233
  • EIN
    68-0359556
Registration is required to get access.